{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T01:10:26Z","timestamp":1788829826629,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ijcard.2024.131857","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T03:48:47Z","timestamp":1707796127000},"page":"131857","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Monitoring and treatment of hypercholesterolemia after an atherosclerotic cardiovascular disease event in Denmark from 2015 to 2020"],"prefix":"10.1016","volume":"402","author":[{"given":"Jakob Kronkvist","family":"Hoe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius M\u00f8lsted","family":"Flege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen","family":"Jimenez-Solem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus Huan","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla Bj\u00f8rn","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2024.131857_bb0005","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2024.131857_bb0010","series-title":"Low Density Lipoprotein Cholesterol and Coronary Heart Disease - Lower Is Better","author":"Breuer","year":"2024"},{"key":"10.1016\/j.ijcard.2024.131857_bb0015","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","article-title":"The changing landscape of atherosclerosis","volume":"592","author":"Libby","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ijcard.2024.131857_bb0020","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1161\/CIRCULATIONAHA.118.034273","article-title":"Long-term Association of low-Density Lipoprotein Cholesterol with Cardiovascular Mortality in individuals at low 10-year risk of atherosclerotic cardiovascular disease","volume":"138","author":"Abdullah","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2024.131857_bb0025","first-page":"1","article-title":"Dyslipid\u00e6mi","volume":"28","author":"Bork","year":"2024","journal-title":"Dan Cardiol Selsk Dan Soc Cardiol"},{"key":"10.1016\/j.ijcard.2024.131857_bb0030","first-page":"15","article-title":"Achievement of the low-density lipoprotein cholesterol goal among patients with dyslipidemia in South Korea","author":"Kim","year":"2020","journal-title":"PloS One"},{"key":"10.1016\/j.ijcard.2024.131857_bb0035","first-page":"e105","article-title":"Adherence to statins and LDL-cholesterol goal attainment","volume":"20","author":"Chi","year":"2014","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.ijcard.2024.131857_bb0040","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/clc.23725","article-title":"Lipid goal attainment in post-acute coronary syndrome patients in China: results from the 6-month real-world dyslipidemia international study II","volume":"44","author":"Gong","year":"2021","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.ijcard.2024.131857_bb0045","first-page":"7","article-title":"Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: Comparison with the National Institute for health and care excellence (NICE) 2014 lipid modification guidelines","author":"Steen","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijcard.2024.131857_bb0050","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.atherosclerosis.2018.02.024","article-title":"Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: insights from Italian general practice","volume":"271","author":"Arca","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2024.131857_bb0055","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s00392-017-1193-z","article-title":"Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins","volume":"107","author":"Fox","year":"2018","journal-title":"Clin. Res. Cardiol."},{"key":"10.1016\/j.ijcard.2024.131857_bb0060","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1475-2840-10-31","article-title":"Trends in utilization of lipid- and blood pressure-lowering agents and goal attainment among the U.S. diabetic population, 1999-2008","volume":"10","author":"Kuznik","year":"2011","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ijcard.2024.131857_bb0065","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/2047487315569401","article-title":"EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries","volume":"23","author":"Kotseva","year":"2016","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.ijcard.2024.131857_bb0070","first-page":"371","volume":"73","author":"\u015eim\u015fek","year":"2021","journal-title":"Rev Investig Clin Organo Hosp Enfermedades Nutr"},{"key":"10.1016\/j.ijcard.2024.131857_bb0075","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1185\/03007995.2014.982751","article-title":"How effective are the ESC\/EAS and 2013 ACC\/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic","volume":"31","author":"Barkas","year":"2015","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ijcard.2024.131857_bb0080","article-title":"Is the novel LDL-cholesterol goal <1.4 mmol\/L achievable without a PCSK9 inhibitor in a chronic coronary population from clinical practice?","author":"Munkhaugen","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.ijcard.2024.131857_bb0085","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1093\/eurheartj\/ehaa034","article-title":"Application of the 2019 ESC\/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study","volume":"41","author":"Allahyari","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2024.131857_bb0090","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1177\/2047487320914115","article-title":"Achievement of European guideline-recommended lipid levels post-percutaneous coronary intervention: A population-level observational cohort study","volume":"28","author":"Harris","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.ijcard.2024.131857_bb0095","doi-asserted-by":"crossref","first-page":"7057","DOI":"10.3390\/jcm11237057","article-title":"Achievement of low-density lipoprotein cholesterol targets in cardiac rehabilitation: impact of the 2019 ESC\/EAS Dyslipidaemia guidelines","volume":"11","author":"Haegele","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ijcard.2024.131857_bb0100","article-title":"The DA VINCI study: is Ireland achieving ESC\/EAS guideline-directed LDL-C goals?","author":"Offiah","year":"2022","journal-title":"Ir. J. Med. Sci."},{"key":"10.1016\/j.ijcard.2024.131857_bb0105","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.atherosclerosis.2020.12.013","article-title":"New cardiovascular prevention guidelines: how to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?","volume":"319","author":"Atar","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2024.131857_bb0110","series-title":"Dyslipidemia","author":"Pappan","year":"2022"},{"key":"10.1016\/j.ijcard.2024.131857_bb0115","doi-asserted-by":"crossref","first-page":"15","DOI":"10.35772\/ghm.2020.01078","article-title":"Secondary dyslipidemia: its treatments and association with atherosclerosis","volume":"3","author":"Yanai","year":"2021","journal-title":"Glob Health Med"},{"key":"10.1016\/j.ijcard.2024.131857_bb0120","series-title":"Copyright, SAS Institute Inc. SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc., Cary, NC, USA","article-title":"The output\/data analysis for this paper was generated using SAS software","year":"2024"},{"key":"10.1016\/j.ijcard.2024.131857_bb0125","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3109\/02813430903335216","article-title":"General practitioners\u2019 adherence to guidelines on management of dyslipidaemia: ADDITION-Denmark","volume":"28","author":"Graversen","year":"2010","journal-title":"Scand. J. Prim. Health Care"},{"key":"10.1016\/j.ijcard.2024.131857_bb0130","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s12872-020-01616-9","article-title":"Lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment after acute coronary syndrome: a Danish population-based cohort study","volume":"20","author":"Kristensen","year":"2020","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.ijcard.2024.131857_bb0135","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1365-2125.2002.01563.x","article-title":"High persistence of statin use in a Danish population: compliance study 1993-1998","volume":"53","author":"Larsen","year":"2002","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijcard.2024.131857_bb0140","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1365-2125.2005.02408.x","article-title":"Statin use after acute myocardial infarction: a nationwide study in Denmark","volume":"60","author":"Rasmussen","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijcard.2024.131857_bb0145","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/ehjqcco\/qcaa004","article-title":"Room for improvement: initiation of lipid-lowering treatment and achievement of lipid target levels\u2014a Danish registry-based study","volume":"7","author":"Rerup","year":"2021","journal-title":"Eur Heart J - Qual Care Clin Outcomes"},{"key":"10.1016\/j.ijcard.2024.131857_bb0150","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.atherosclerosis.2016.11.025","article-title":"Extent of undertreatment and overtreatment with cholesterol-lowering therapy according to European guidelines in 92,348 Danes without ischemic cardiovascular disease and diabetes in 2004\u20132014","volume":"257","author":"Langsted","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcard.2024.131857_bb0155","first-page":"40","article-title":"Lipid-lowering therapy and goal achievement in high-risk patients from French general practice","year":"2018","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ijcard.2024.131857_bb0160","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.thromres.2019.09.034","article-title":"Cardiovascular event rates and trajectories of LDL-cholesterol levels and lipid-lowering therapy in patients with atherosclerotic cardiovascular disease: A population-based cohort study","volume":"183","author":"Sundb\u00f8ll","year":"2019","journal-title":"Thromb. Res."},{"key":"10.1016\/j.ijcard.2024.131857_bb0170","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/eurheartj\/ehv641","article-title":"Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study","volume":"37","author":"Nielsen","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2024.131857_bb0175","first-page":"cmac090","article-title":"Factors associated with statin discontinuation near end of life in a Danish primary health care cohort","author":"Engell","year":"2022","journal-title":"Fam. Pract."},{"key":"10.1016\/j.ijcard.2024.131857_bb0180","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.sapharm.2017.09.002","article-title":"Medication non-adherence and uncertainty: information-seeking and processing in the Danish LIFESTAT survey","volume":"14","author":"Kriegbaum","year":"2018","journal-title":"Res. Soc. Adm. Pharm."},{"key":"10.1016\/j.ijcard.2024.131857_bb0185","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ijcard.2024.131857_bb0190","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/eurjpc\/zwaa128","volume":"29","author":"De Bacquer","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.ijcard.2024.131857_bb0195","article-title":"Effectiveness of telehealth cardiac rehabilitation programs on health outcomes of patients with coronary heart diseases: AN UMBRELLA REVIEW","author":"Shi","year":"2023","journal-title":"J. Cardiopulm. Rehabil. Prev."},{"key":"10.1016\/j.ijcard.2024.131857_bb0200","first-page":"739","article-title":"Digital literacy as a potential barrier to implementation of cardiology tele-visits after COVID-19 pandemic: the INFO-COVID survey","volume":"18","author":"Boriani","year":"2021","journal-title":"J Geriatr Cardiol JGC"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016752732400264X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016752732400264X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T21:04:54Z","timestamp":1759093494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016752732400264X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":39,"alternative-id":["S016752732400264X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.131857","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monitoring and treatment of hypercholesterolemia after an atherosclerotic cardiovascular disease event in Denmark from 2015 to 2020","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2024.131857","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"131857"}}